TME Pharma NV (XPAR:ALTME) ROCE % : 0.00% (As of Dec. 2023)

View and export this data going back to 2016. Start your Free Trial

What is TME Pharma NV ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. TME Pharma NV's annualized ROCE % for the quarter that ended in Dec. 2023 was 0.00%.

TME Pharma NV ROCE % Historical Data

The historical data trend for TME Pharma NV's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TME Pharma NV ROCE % Chart

TME Pharma NV Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-178.75

-211.24

-711.31

TME Pharma NV Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROCE %	Get a 7-Day Free Trial													-199.82	-446.44	-1,654.12	-	-

TME Pharma NV ROCE % Calculation

TME Pharma NV's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-5.216	/	( ( (5.241 - 6.446)	+	(2.491 - 2.785) )	/ 2 )
	=	-5.216	/	( (-1.205	+	-0.294)	/ 2 )
	=	-5.216	/	-0.7495
	=	695.93 %

TME Pharma NV's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Jun. 2023 )		(Q: Dec. 2023 )
	=	-5.394	/	( ( (3.462 - 3.62)	+	(2.491 - 2.785) )	/ 2 )
	=	-5.394	/	( ( -0.158	+	-0.294 )	/ 2 )
	=	-5.394	/	-0.226
	=	0 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

TME Pharma NV (XPAR:ALTME) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

TME Pharma NV ROCE % Related Terms

Thank you for viewing the detailed overview of TME Pharma NV's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

TME Pharma NV (XPAR:ALTME) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TME Pharma NV (XPAR:ALTME) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

0N6A:Germany

Address

Max-Dohrn-Street 8-10, Berlin, DEU, 10589

Website

https://www.tmepharma.com

TME Pharma NV is a clinical-stage biopharmaceutical company engaged in improving cancer treatment by targeting the tumor microenvironment and focusing on the improvement in the effectiveness of cancer therapies. Its product candidates are; NOX-A12 and NOX-E36 are based on a new class of drug first developed by TME Pharma called Spiegelmers, which offer specific advantages over other drug classes.

TME Pharma NV (XPAR:ALTME) Headlines

No Headlines